---
schema_version: "secwatch.filing_event.v1"
accession: "0000313143-24-000009"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:17:31.964568+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Haemonetics to acquire Attune Medical for $160M upfront; device complements EP portfolio

## Summary
- Upfront cash $160M plus contingent consideration based on sales growth and milestones.
- Attune Medical's ensoETM device reduces esophageal injury during cardiac ablation; revenue $22M in 2023, doubled YoY.
- Transaction expected to close in Q1 fiscal 2025 (April-June 2024) subject to customary conditions.
- Haemonetics expects immediate accretion to revenue and earnings growth; financed via cash and revolver.

## SEC filing metadata
- accession: 0000313143-24-000009
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000031314324000009/0000313143-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000031314324000009/hae-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313143-24-000009
- JSON: https://secwatch.observer/filing/0000313143-24-000009.json
- Plain text: https://secwatch.observer/filing/0000313143-24-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.